Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Honeysuckle Granules is a traditional Chinese medicine (TCM) over-the-counter (OTC) oral preparation developed and manufactured by Guangzhou Nuojin Pharmaceutical. Formulated as granules for oral administration, this preparation is a compound mixture typically derived from the extracts of *Lonicera japonica* (Honeysuckle), *Forsythia suspensa*, and *Scutellaria baicalensis*. In the context of traditional Chinese medicine, it is primarily indicated for clearing heat and detoxifying (Qingre Jiedu), which clinically translates to the treatment of wind-heat type common colds, sore throats, and inflammatory conditions such as boils and swelling. The therapeutic efficacy is attributed to the synergistic effects of its herbal constituents, which exhibit anti-inflammatory, antibacterial, and antiviral properties. The product is approved and marketed in China for these indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound honeysuckle granules.